PointState Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

PointState Capital’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-8,700	Closed	-$1.54M	–	181
2021 Q3	$1.54M	Buy	+8,700	New	+$1.4M	0.03%	122
2018 Q4	–	Sell	-241,625	Closed	-$11.4M	–	145
2018 Q3	$11.4M	Buy	+241,625	New	+$13.5M	0.15%	74
2018 Q2	–	Sell	-298,500	Closed	-$9.16M	–	205
2018 Q1	$9.16M	Buy	+298,500	New	+$8.29M	0.1%	102
2015 Q2	–	Sell	-25,000	Closed	-$733K	–	182
2015 Q1	$733K	Buy	+25,000	New	+$586K	0.01%	113

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PointState Capital's MRTX Position: Q4 2021 in Review

PointState Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2021, closing a stake of 8,700 shares — an estimated $1.54M sold.

PointState Capital first reported a position in MRTX in Q1 2015 and held it in 4 quarters. The position peaked at $11.4M in Q3 2018. 260 funds tracked by Wall St. Rank hold MRTX as of Q4 2021.

PointState Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
PointState Capital sold 8,700 Mirati Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $1.54M.
PointState Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2015 and held it in 4 quarters.
PointState Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $11.4M in Q3 2018.
260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2021.

Based on PointState Capital's 13F filing for Q4 2021, filed 11 Feb 2022.